Evidence map›Paper›PMID 30988384›Full record

ArticleScientific reports2019

3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15.

Martin K Rasmussen, Nikolay Kardjilov, Cristiano L P Oliveira, Benjamin Watts, Julie Villanova, Viviane Fongaro Botosso, Osvaldo A Sant'Anna, Marcia C A Fantini, Heloisa N Bordallo

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to ControlInternational journal of molecular sciences · 2023
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 6 countries.

Martin K RasmussenNiels Bohr Institute, University of Copenhagen, Copenhagen, Denmark.
Nikolay KardjilovHelmholtz Center Berlin for Materials and Energy, Berlin, Germany.
Cristiano L P OliveiraInstitute of Physics, São Paulo, Brazil.
Benjamin WattsPaul Scherrer Institute, Villigen, Switzerland.ORCID http://orcid.org/0000-0003-2330-2338
Julie VillanovaESRF-The European Synchrotron, ID16B, Grenoble, France.
Viviane Fongaro BotossoVirology Laboratory, Butantan Institute, São Paulo, Brazil.
Osvaldo A Sant'AnnaImmunochemistry Laboratory, Butantan Institute, São Paulo, Brazil.
Marcia C A FantiniInstitute of Physics, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-6862-8716
Heloisa N BordalloNiels Bohr Institute, University of Copenhagen, Copenhagen, Denmark. bordallo@nbi.ku.dk.ORCID http://orcid.org/0000-0003-0750-0553
Instituto Butantan · BRUniversity of Copenhagen · DKEuropean Synchrotron Radiation Facility · FRHelmholtz-Zentrum Berlin für Materialien und Energie · DEPaul Scherrer Institute · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing a technology that enables oral vaccines to work efficiently remains a considerable effort since a number of difficulties must be addressed. The key objective being to ensure the safe passage through the harsh conditions within the gastrointestinal tract, promoting delivery that induces enhanced immune response. In the particular case of hepatitis B, the oral formulation in the nanostructured silica SBA-15 is a viable approach. As a result of its porous structure, low toxicity and structural stability, SBA-15 is capable to protect and release the hepatitis B surface antigen (HBsAg), used in the vaccination scheme, at the desired destination. Furthermore, when compared to the currently used injection based delivery method, better or similar antibody response has been observed. However, information about the organisation of the antigen protein remains unknown. For instance, HBsAg is too large to enter the 10 nm ordered mesopores of SBA-15 and has a tendency to agglomerate when protected by the delivery system. Here we report on the pH dependence of HBsAg aggregation in saline solution investigated using small angle X-rays scattering that resulted in an optimisation of the encapsulation conditions. Additionally, X-ray microscopy combined with neutron and X-ray tomography provided full 3D information of the HBsAg clustering (i.e. agglomeration) inside the SBA-15 macropores. This method enables the visualisation of the organisation of the antigen in the interior of the delivery system, where agglomerated HBsAg coexists with its immunological effective uniformly distributed counterpart. This new approach, to be taken into account while preparing the formulation, can greatly help in the understanding of clinical studies and advance new formulations.

Indexed as

Administration, OralChemistry, PharmaceuticalDrug CarriersDrug CompoundingDrug LiberationDynamic Light ScatteringGastrointestinal TractHepatitis BHepatitis B Surface AntigensHepatitis B VaccinesHydrogen-Ion ConcentrationImaging, Three-DimensionalNanostructuresPorosityProtein AggregatesScattering, Small AngleDrug CarriersHepatitis B Surface AntigensHepatitis B VaccinesProtein AggregatesSBA-15Silicon Dioxide

Identifiers

PMID30988384
PMCPMC6465313
OpenAlexW2937068938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.